Rechallenging with anthracyclines and taxanes in metastatic breast cancer.
Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse following adjuvant therapy, and whether there is a role for rechallenging in the metastatic setting with the same agent, or class of agent, that has been utilized in the adjuvant setting. This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials.
Palmieri
Carlo
C
Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK. c.palmieri@imperial.ac.uk
Krell
Jonathan
J
James
Colin R
CR
Harper-Wynne
Catherine
C
Misra
Vivek
V
Cleator
Susan
S
Miles
David
D
D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy; D019233:Retreatment; D043823:Taxoids / Q000008:administration & dosage
D018943:Anthracyclines; D043823:Taxoids
J Clin Oncol. 2003 Mar 15;21(6):976-83
12637460
Oncologist. 2002;7 Suppl 6:4-12
12454314
Ann Oncol. 2004 Oct;15(10):1517-26
15367413
J Clin Oncol. 2009 Dec 10;27(35):5906-10
19858391
J Clin Oncol. 2008 Jan 1;26(1):44-53
18165639
Cancer. 1984 Oct 1;54(7):1252-5
6467151
Ann Oncol. 1994 Jan;5(1):95-7
8172802
J Clin Oncol. 1996 Jun;14(6):1877-84
8656256
Clin Breast Cancer. 2007 Dec;7(11):850-6
18269774
J Clin Oncol. 2009 Oct 20;27(30):4966-72
19720913
J Natl Cancer Inst. 2008 Jan 16;100(2):121-33
18182617
Lancet. 2009 May 16;373(9676):1681-92
19447249
J Clin Oncol. 2009 Sep 20;27(27):4522-9
19687336
Oncology. 1994 Nov-Dec;51(6):518-22
7970497
Cancer. 1981 Jun 15;47(12):2798-802
7260870
J Clin Oncol. 2010 Jul 10;28(20):3239-47
20498403
Ann Oncol. 2009 Jul;20(7):1210-5
19254942
Cancer. 1988 Feb 1;61(3):415-9
3338011
Ann Oncol. 2007 Jun;18 Suppl 6:vi66-9
17591836
Ann Oncol. 2005 Nov;16(11):1762-71
16148021
Cancer. 2001 Nov 1;92(9):2267-72
11745280
J Clin Oncol. 2003 Sep 1;21(17):3249-54
12947059
Ann Intern Med. 1983 Apr;98(4):472-4
6301321
J Clin Oncol. 2004 Oct 1;22(19):3893-901
15459210
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Breast Cancer Res Treat. 2005 Feb;89(3):237-41
15754121
Cancer. 1997 Jun 1;79(11):2137-46
9179060
J Natl Cancer Inst. 2008 Jun 4;100(11):805-14
18505968
J Clin Oncol. 1998 Nov;16(11):3502-8
9817267
J Clin Oncol. 1994 Jun;12(6):1259-65
8201387
J Clin Oncol. 1996 Mar;14(3):764-73
8622022
Ann Oncol. 2003 Jun;14(6):833-42
12796019
J Clin Oncol. 2006 Dec 20;24(36):5664-71
17116941
Oncology. 1990;47(1):4-8
2300383
J Clin Oncol. 1989 May;7(5):560-71
2468745
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Cochrane Database Syst Rev. 2004;(3):CD003374
15266482
J Clin Oncol. 2001 Mar 1;19(5):1444-54
11230490
Br J Cancer. 2006 May 8;94(9):1233-6
16622454
J Clin Oncol. 1998 Oct;16(10):3362-8
9779713
Am J Clin Oncol. 2007 Apr;30(2):133-8
17414461
Clin Breast Cancer. 2004 Jan;4 Suppl 3:S113-6
14754468
J Clin Oncol. 2008 Sep 1;26(25):4092-9
18678836
J Clin Oncol. 1984 Apr;2(4):275-81
6584561
Cancer. 2002 Jan 1;94(1):25-36
11815957
J Clin Oncol. 2001 Nov 15;19(22):4216-23
11709565
J Clin Oncol. 1996 Apr;14(4):1146-55
8648369
J Clin Oncol. 1986 May;4(5):672-7
3517241
J Clin Oncol. 2001 Apr 15;19(8):2232-9
11304776
Ann Intern Med. 1981 Dec;95(6):694-7
7305147
Clin Breast Cancer. 2004 Dec;5(5):353-7
15585072
J Clin Oncol. 1994 Aug;12(8):1639-47
8040676
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Br J Cancer. 1998 Jun;77(12):2257-63
9649142
Anticancer Drugs. 2006 Jun;17(5):587-95
16702817
Ann Intern Med. 1979 May;90(5):761-3
434676
Ann Oncol. 2004 Mar;15(3):440-9
14998846
Br J Cancer. 2006 Jun 5;94(11):1615-20
16685267
J Clin Oncol. 2005 Jun 1;23(16):3686-96
15897552
Breast Cancer Res Treat. 2007 Jul;103(3):313-8
17063267
Gynecol Oncol. 1985 Jun;21(2):167-76
3921437
Br J Cancer. 2004 Mar 8;90(5):962-7
14997190
Lancet Oncol. 2007 Mar;8(3):219-25
17329192
Cancer. 2000 Sep 1;89(5):1037-47
10964334
Cancer Chemother Pharmacol. 1988;21(1):45-8
2830043
Am J Clin Oncol. 1989 Feb;12(1):57-62
2643296
Cancer Chemother Pharmacol. 2006 May;57(5):615-23
16163541
J Clin Oncol. 2005 Nov 20;23(33):8322-30
16293863
J Clin Oncol. 2007 Nov 20;25(33):5210-7
17968020
Ann Intern Med. 1979 Nov;91(5):710-7
496103
Anticancer Drugs. 2000 Sep;11(8):617-21
11081452
J Clin Oncol. 2005 Feb 1;23(4):792-9
15681523
Oncologist. 2002;7 Suppl 6:20-8
12454316
Cancer. 2001 Mar 15;91(6):1079-89
11267952
Breast J. 2004 Nov-Dec;10(6):509-13
15569207
Br J Cancer. 1998 Jun;77(11):1950-6
9667673
J Clin Oncol. 1994 Jan;12(1):45-9
8270982